FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2300980227> ?p ?o ?g. }

• W2300980227 endingPage "8" @default.
• W2300980227 startingPage "8" @default.
• W2300980227 abstract "Studies on gene expression in response to therapy have led to the discovery of pharmacogenomics biomarkers and advances in precision medicine. Whole transcriptome sequencing (RNA-seq) is an emerging tool for profiling gene expression and has received wide adoption in the biomedical research community. However, its value in regulatory decision making requires rigorous assessment and consensus between various stakeholders, including the research community, regulatory agencies, and industry. The FDA-led SEquencing Quality Control (SEQC) consortium has made considerable progress in this direction, and is the subject of this review. Specifically, three RNA-seq platforms (Illumina HiSeq, Life Technologies SOLiD, and Roche 454) were extensively evaluated at multiple sites to assess cross-site and cross-platform reproducibility. The results demonstrated that relative gene expression measurements were consistently comparable across labs and platforms, but not so for the measurement of absolute expression levels. As part of the quality evaluation several studies were included to evaluate the utility of RNA-seq in clinical settings and safety assessment. The neuroblastoma study profiled tumor samples from 498 pediatric neuroblastoma patients by both microarray and RNA-seq. RNA-seq offers more utilities than microarray in determining the transcriptomic characteristics of cancer. However, RNA-seq and microarray-based models were comparable in clinical endpoint prediction, even when including additional features unique to RNA-seq beyond gene expression. The toxicogenomics study compared microarray and RNA-seq profiles of the liver samples from rats exposed to 27 different chemicals representing multiple toxicity modes of action. Cross-platform concordance was dependent on chemical treatment and transcript abundance. Though both RNA-seq and microarray are suitable for developing gene expression based predictive models with comparable prediction performance, RNA-seq offers advantages over microarray in profiling genes with low expression. The rat BodyMap study provided a comprehensive rat transcriptomic body map by performing RNA-Seq on 320 samples from 11 organs in either sex of juvenile, adolescent, adult and aged Fischer 344 rats. Lastly, the transferability study demonstrated that signature genes of predictive models are reciprocally transferable between microarray and RNA-seq data for model development using a comprehensive approach with two large clinical data sets. This result suggests continued usefulness of legacy microarray data in the coming RNA-seq era. In conclusion, the SEQC project enhances our understanding of RNA-seq and provides valuable guidelines for RNA-seq based clinical application and safety evaluation to advance precision medicine." @default.
• W2300980227 created "2016-06-24" @default.
• W2300980227 creator A5009034274 @default.
• W2300980227 creator A5014434082 @default.
• W2300980227 creator A5024782080 @default.
• W2300980227 creator A5062984211 @default.
• W2300980227 creator A5070704034 @default.
• W2300980227 date "2016-03-15" @default.
• W2300980227 modified "2023-10-12" @default.
• W2300980227 title "Comprehensive Assessments of RNA-seq by the SEQC Consortium: FDA-Led Efforts Advance Precision Medicine" @default.
• W2300980227 cites W1831052262 @default.
• W2300980227 cites W1880949099 @default.
• W2300980227 cites W1969885044 @default.
• W2300980227 cites W1989996002 @default.
• W2300980227 cites W2010637767 @default.
• W2300980227 cites W2030677229 @default.
• W2300980227 cites W2039521726 @default.
• W2300980227 cites W2060842569 @default.
• W2300980227 cites W2064397275 @default.
• W2300980227 cites W2073380432 @default.
• W2300980227 cites W2090859961 @default.
• W2300980227 cites W2093288248 @default.
• W2300980227 cites W2101851382 @default.
• W2300980227 cites W2121211805 @default.
• W2300980227 cites W2124140824 @default.
• W2300980227 cites W2130007124 @default.
• W2300980227 cites W2138309100 @default.
• W2300980227 cites W2151876471 @default.
• W2300980227 cites W2283706030 @default.
• W2300980227 doi "https://doi.org/10.3390/pharmaceutics8010008" @default.
• W2300980227 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4810084" @default.
• W2300980227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26999190" @default.
• W2300980227 hasPublicationYear "2016" @default.
• W2300980227 type Work @default.
• W2300980227 sameAs 2300980227 @default.
• W2300980227 citedByCount "44" @default.
• W2300980227 countsByYear W23009802272016 @default.
• W2300980227 countsByYear W23009802272017 @default.
• W2300980227 countsByYear W23009802272018 @default.
• W2300980227 countsByYear W23009802272019 @default.
• W2300980227 countsByYear W23009802272020 @default.
• W2300980227 countsByYear W23009802272021 @default.
• W2300980227 countsByYear W23009802272022 @default.
• W2300980227 countsByYear W23009802272023 @default.
• W2300980227 crossrefType "journal-article" @default.
• W2300980227 hasAuthorship W2300980227A5009034274 @default.
• W2300980227 hasAuthorship W2300980227A5014434082 @default.
• W2300980227 hasAuthorship W2300980227A5024782080 @default.
• W2300980227 hasAuthorship W2300980227A5062984211 @default.
• W2300980227 hasAuthorship W2300980227A5070704034 @default.
• W2300980227 hasBestOaLocation W23009802271 @default.
• W2300980227 hasConcept C104317684 @default.
• W2300980227 hasConcept C107397762 @default.
• W2300980227 hasConcept C150194340 @default.
• W2300980227 hasConcept C162317418 @default.
• W2300980227 hasConcept C163763905 @default.
• W2300980227 hasConcept C170734499 @default.
• W2300980227 hasConcept C18431079 @default.
• W2300980227 hasConcept C186836561 @default.
• W2300980227 hasConcept C32220436 @default.
• W2300980227 hasConcept C54355233 @default.
• W2300980227 hasConcept C60644358 @default.
• W2300980227 hasConcept C67705224 @default.
• W2300980227 hasConcept C70721500 @default.
• W2300980227 hasConcept C86803240 @default.
• W2300980227 hasConcept C93231420 @default.
• W2300980227 hasConceptScore W2300980227C104317684 @default.
• W2300980227 hasConceptScore W2300980227C107397762 @default.
• W2300980227 hasConceptScore W2300980227C150194340 @default.
• W2300980227 hasConceptScore W2300980227C162317418 @default.
• W2300980227 hasConceptScore W2300980227C163763905 @default.
• W2300980227 hasConceptScore W2300980227C170734499 @default.
• W2300980227 hasConceptScore W2300980227C18431079 @default.
• W2300980227 hasConceptScore W2300980227C186836561 @default.
• W2300980227 hasConceptScore W2300980227C32220436 @default.
• W2300980227 hasConceptScore W2300980227C54355233 @default.
• W2300980227 hasConceptScore W2300980227C60644358 @default.
• W2300980227 hasConceptScore W2300980227C67705224 @default.
• W2300980227 hasConceptScore W2300980227C70721500 @default.
• W2300980227 hasConceptScore W2300980227C86803240 @default.
• W2300980227 hasConceptScore W2300980227C93231420 @default.
• W2300980227 hasIssue "1" @default.
• W2300980227 hasLocation W23009802271 @default.
• W2300980227 hasLocation W23009802272 @default.
• W2300980227 hasLocation W23009802273 @default.
• W2300980227 hasLocation W23009802274 @default.
• W2300980227 hasLocation W23009802275 @default.
• W2300980227 hasLocation W23009802276 @default.
• W2300980227 hasOpenAccess W2300980227 @default.
• W2300980227 hasPrimaryLocation W23009802271 @default.
• W2300980227 hasRelatedWork W2036350179 @default.
• W2300980227 hasRelatedWork W2068142083 @default.
• W2300980227 hasRelatedWork W2071084184 @default.
• W2300980227 hasRelatedWork W2121123734 @default.
• W2300980227 hasRelatedWork W2159063798 @default.
• W2300980227 hasRelatedWork W2470631360 @default.
• W2300980227 hasRelatedWork W2581299237 @default.
• W2300980227 hasRelatedWork W2999563835 @default.

• next